203 related articles for article (PubMed ID: 20493256)
1. Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium.
Catherino WH; Malik M; Driggers P; Chappel S; Segars J; Davis J
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):279-86. PubMed ID: 20493256
[TBL] [Abstract][Full Text] [Related]
2. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth.
Yoshida S; Ohara N; Xu Q; Chen W; Wang J; Nakabayashi K; Sasaki H; Morikawa A; Maruo T
Semin Reprod Med; 2010 May; 28(3):260-73. PubMed ID: 20414849
[TBL] [Abstract][Full Text] [Related]
3. Locostatin, a disrupter of Raf kinase inhibitor protein, inhibits extracellular matrix production, proliferation, and migration in human uterine leiomyoma and myometrial cells.
Janjusevic M; Greco S; Islam MS; Castellucci C; Ciavattini A; Toti P; Petraglia F; Ciarmela P
Fertil Steril; 2016 Nov; 106(6):1530-1538.e1. PubMed ID: 27565262
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of analysis of estrogen and progesterone receptors in human uterine tissues].
Maleeva A; Milkov V
Akush Ginekol (Mosk); 1991 May; (5):55-7. PubMed ID: 1897675
[TBL] [Abstract][Full Text] [Related]
5. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
6. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
Chen W; Ohara N; Wang J; Xu Q; Liu J; Morikawa A; Sasaki H; Yoshida S; Demanno DA; Chwalisz K; Maruo T
J Clin Endocrinol Metab; 2006 Apr; 91(4):1296-304. PubMed ID: 16464945
[TBL] [Abstract][Full Text] [Related]
7. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
Maruo T; Ohara N; Matsuo H; Xu Q; Chen W; Sitruk-Ware R; Johansson ED
Contraception; 2007 Jun; 75(6 Suppl):S99-103. PubMed ID: 17531625
[TBL] [Abstract][Full Text] [Related]
8. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
9. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.
Ohara N; Morikawa A; Chen W; Wang J; DeManno DA; Chwalisz K; Maruo T
Reprod Sci; 2007 Dec; 14(8 Suppl):20-7. PubMed ID: 18089606
[TBL] [Abstract][Full Text] [Related]
11. Versican Proteolysis by ADAMTS Proteases and Its Influence on Sex Steroid Receptor Expression in Uterine Leiomyoma.
Gueye NA; Mead TJ; Koch CD; Biscotti CV; Falcone T; Apte SS
J Clin Endocrinol Metab; 2017 May; 102(5):1631-1641. PubMed ID: 28323982
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma.
Ohara N
Clin Exp Obstet Gynecol; 2005; 32(1):9-11. PubMed ID: 15864926
[TBL] [Abstract][Full Text] [Related]
13. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs).
Chwalisz K; Garg R; Brenner R; Slayden O; Winkel C; Elger W
Reprod Biol Endocrinol; 2006; 4 Suppl 1(Suppl 1):S8. PubMed ID: 17118172
[TBL] [Abstract][Full Text] [Related]
14. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells.
Wang J; Ohara N; Wang Z; Chen W; Morikawa A; Sasaki H; DeManno DA; Chwalisz K; Maruo T
Hum Reprod; 2006 Jul; 21(7):1869-77. PubMed ID: 16613890
[TBL] [Abstract][Full Text] [Related]
15. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer.
Morikawa A; Ohara N; Xu Q; Nakabayashi K; DeManno DA; Chwalisz K; Yoshida S; Maruo T
Hum Reprod; 2008 Apr; 23(4):944-51. PubMed ID: 18281245
[TBL] [Abstract][Full Text] [Related]
16. Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures.
Severino MF; Murray MJ; Brandon DD; Clinton GM; Burry KA; Novy MJ
Mol Hum Reprod; 1996 Nov; 2(11):823-8. PubMed ID: 9237221
[TBL] [Abstract][Full Text] [Related]
17. Endocrinological properties of two novel nonsteroidal progesterone receptor modulators, CP8816 and CP8863.
Kurata Y; Tabata Y; Shinei R; Iizuka Y; Masuda NT; Kurihara K; Okonogi T; Hoshiko S
J Pharmacol Exp Ther; 2005 May; 313(2):916-20. PubMed ID: 15743919
[TBL] [Abstract][Full Text] [Related]
18. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system.
Maruo T; Ohara N; Yoshida S; Nakabayashi K; Sasaki H; Xu Q; Chen W; Yamada H
Contraception; 2010 Nov; 82(5):435-41. PubMed ID: 20933117
[TBL] [Abstract][Full Text] [Related]
19. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
20. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies.
Wagenfeld A; Saunders PT; Whitaker L; Critchley HO
Expert Opin Ther Targets; 2016 Sep; 20(9):1045-54. PubMed ID: 27138351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
